SHIELD study fails to protect prospects for GlaxoSmithKline's vercirnon
This article was originally published in Scrip
Executive Summary
On 23 August 2013, GlaxoSmithKline announced that its oral Crohn's disease candidate vercirnon had failed to meet its primary endpoint in SHIELD-1, the first of four Phase III studies investigating the small molecule inhibitor of C-C chemokine receptor type-9 (CCR9) as a treatment for adults with moderate to severe Crohn's disease. The Phase III failure follows the publication of less than convincing Phase II/III study data. While the IBD market may not suffer from the likely loss of vercirnon, the absence of a commercial bridgehead leaves GlaxoSmithKline excluded from the inflammatory bowel disease (IBD) area.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.